Pharmaceutical companies at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

20 pharmaceutical companies are at ACT 2026 — 79 presentations on the program. Most represented: Johnson & Johnson (8 on the program), Novartis (6 on the program), Lilly (5 on the program). 18 of them have their own page in this guide. As of Oct 8, 2026.

All 231 organizations at ACT 2026 →

Showing 1–7 of 20 organizations

Organization	ACT 2026 Attendance
Johnson & Johnson New Brunswick, NJ
jnj.com Pharmaceutical companies Healthcare company whose Innovative Medicine arm, formerly Janssen, discovers, develops and markets prescription medicines.	Talk Sun Nov 15 8:00am–8:05am Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4) Introduction (CE4-1) Regulatory Session Sun Nov 15 8:00am–11:30am Working with Global Regulators for Streamlined Nonclinical Development (CE4) Regulatory · with MEC Regulatory & Toxicology Consulting 8:00amIntroduction (CE4-1)Johnson & Johnson 8:05amTop Tips for Successful Nonclinical Regulatory Interaction (CE4-2)Charles River 8:30amIdeal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)U.S. Food and Drug Administration 9:00amIdeal Interaction During Drug Development: European Regulator's Perspective (CE4-4)Medicines Evaluation Board 10:00amSponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)Lilly 10:30amInteractive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)MEC Regulatory & Toxicology Consulting Talk Sun Nov 15 9:00am–9:30am Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) Conducting an EFD Study: The Essentials of Getting it Right (CE3-4) DART Talk Sun Nov 15 3:00pm–3:20pm Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6) Effectively Evaluating, Understanding, and Communicating the Risky Behavior of Immunotherapies: The Complex and Diverse Role of a Project (Program) Toxicologist (CE6-5) Immunotoxicology Talk Mon Nov 16 2:00pm–2:05pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) Introduction (S06-1) Translational safety Session Mon Nov 16 2:00pm–5:00pm Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) Translational safety 2:00pmIntroduction (S06-1)Johnson & Johnson 2:05pmDe-risking of Nonclinical Renal Safety Signals through Investigative Studies and Robust Clinical Monitoring (S06-2)Bristol Myers Squibb 2:40pmDILI Whodunnit: Responding to Drug Induced Liver Injury during TAK-994 Clinical Trials (S06-3)Takeda 3:45pmClinical Holds in the Development of Novel Genetic Medicines (S06-4)Bioepisteme 4:20pmProspective and Retrospective Risk Assessments of Safety Signals for a Rare Disease Biotherapeutic (S06-5)Amgen Poster Mon Nov 16 5:00pm–6:30pm Validation of Organ-Specific Risk Estimates Derived from a Gene-Based Machine Learning Algorithm (P447) Nelson Exhibit Ballroom · Poster P447 In silico and AI Talk Tue Nov 17 3:45pm–4:15pm Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10) Evolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4) Biologics and new modalities · Safety pharmacology Talk Wed Nov 18 2:25pm–2:45pm Part of Invisible Ingredients, Critical Functions: The Risk Narrative around Excipients and PFAS (S17) Risk Communication and Perception of Forever Chemicals and the Consequences for Pharma (S17-2) Chemical risk assessment
Novartis Basel, Switzerland
novartis.com Pharmaceutical companies Swiss pharmaceutical company; its preclinical safety teams present on first-in-human dosing, oligonucleotides, minipig lactation studies and excipient safety.	Session Sun Nov 15 8:00am–11:30am First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Translational safety · with Boehringer Ingelheim 8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox 8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics 8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri 9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis 10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis 10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim Talk Sun Nov 15 9:10am–9:30am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Inter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4) Translational safety Talk Sun Nov 15 10:00am–10:25am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Crossing the Species Divide in Inhaled Dosing (CE1-5) Inhalation toxicology · Translational safety Poster Mon Nov 16 5:00pm–6:30pm Coadministration of Two GalNAc-Conjugated siRNAs in Rats Produces Nonadverse Effects Similar to the Findings of the Individual siRNAs in General Toxicology Studies (P405) Nelson Exhibit Ballroom · Poster P405 Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm Comparison between the Intravenous (IV) and Subcutaneous (SC) Routes of Administration of Inclisiran on Pharmacodynamics (PD), Toxicokinetics (TK) and Safety in the Nonhuman Primate (P409) Nelson Exhibit Ballroom · Poster P409 Biologics and new modalities · Bioanalysis and biomarkers Poster Mon Nov 16 5:00pm–6:30pm Neonatal Excipient Safety: Risk Assessment Considerations for Ethyl Benzoate in a Vulnerable Patient Population (P427) Nelson Exhibit Ballroom · Poster P427 Chemical risk assessment Poster Mon Nov 16 5:00pm–6:30pm The Göttingen Minipig as a Preclinical Model of Drug Transfer during Lactation (P440) Nelson Exhibit Ballroom · Poster P440 DART · Animal models Talk Wed Nov 18 2:05pm–2:30pm Part of Hot Topics (S18) Cross-Industry Survey of Nonclinical Development Strategies for Oligonucleotide Therapeutics: Species Selection, Dose Setting, and Translational Approaches (S18-2) Biologics and new modalities · Animal models
Lilly Indianapolis, IN	◆Diamond Supporter
lilly.com Pharmaceutical companiesDiamond Supporter Global pharmaceutical company with medicines in diabetes, obesity, oncology, immunology and neuroscience.	Talk Sun Nov 15 10:00am–10:35am Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) Interpreting EFD Study Data (CE3-5) DART Talk Sun Nov 15 10:00am–10:30am Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4) Sponsor Strategies for Successful Regulatory Agency Interactions (CE4-5) Regulatory Talk Tue Nov 17 9:50am–10:15am Part of Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs (S08) Nonclinical Developmental Considerations for Neuronal Delivery of Oligonucleotides (S08-4) Biologics and new modalities · Neurotoxicology Session Tue Nov 17 2:00pm–5:00pm From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12) New approach methods · Regulatory · with Neurocrine Biosciences 2:00pmWelcome and Overview (S12-1)Neurocrine Biosciences 2:05pmA Brief History of Regulatory Efforts to Reduce Animal Use in Drug Development (S12-2)Lilly 2:20pmThe FDA Roadmap and Adoption of NAMs for Regulatory Decision Making (S12-3)U.S. Food and Drug Administration 2:50pmIndustry Experience: DruSafe/BioSafe Survey (S12-4)Agios Pharmaceuticals 3:45pmNAM Qualification Pathway for an ISTAND Drug Development Tool (S12-5)Integral Molecular Talk Tue Nov 17 2:05pm–2:20pm Part of From Policy to Practice: Progress on the FDA’s 2025 Roadmap to Reduce Animal Use in Antibody Platform Development (S12) A Brief History of Regulatory Efforts to Reduce Animal Use in Drug Development (S12-2) Regulatory · New approach methods Talk Wed Nov 18 9:00am–9:10am Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13) Introduction on CNS Risk Assessment (S13-1) Neurotoxicology Session Wed Nov 18 9:00am–12:00pm Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13) Neurotoxicology · with Charles River 9:00amIntroduction on CNS Risk Assessment (S13-1)Lilly 9:10amNeurotoxicology in General Toxicology Studies: Interactive Case Studies to Explore Common Challenges, Regulatory Strategies, and Innovative Approaches (S13-2)Charles River 9:40amMechanistic Insights into Species-Specific Seizure Susceptibility (S13-3)ApconiX 10:45amThe Complexity of Drug Development Illustrated with Nav1.7-Associated Dysautonomia (S13-4)Genentech 11:10amCNS NAMs for modeling of neural plasticity and learning in neural organoids (S13-5)Johns Hopkins University
Bristol Myers Squibb
bms.com Pharmaceutical companies Global pharmaceutical company with marketed medicines in oncology, immunology, cardiovascular disease and neuroscience.	Talk Mon Nov 16 2:05pm–2:40pm Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06) De-risking of Nonclinical Renal Safety Signals through Investigative Studies and Robust Clinical Monitoring (S06-2) Translational safety Poster Mon Nov 16 5:00pm–6:30pm Terminology Translation of SEND and MedDRA for Enabling Translational Safety: Challenges, Use Cases, and Collaborative Opportunities (P528) Nelson Exhibit Ballroom · Poster P528 Study data · Translational safety Poster Mon Nov 16 5:00pm–6:30pm Unlocking the Value of Shared Toxicology Data: How BioCelerate Members Use Historical Data to Support Preclinical Research (P445) Nelson Exhibit Ballroom · Poster P445 Study data Talk Tue Nov 17 2:05pm–2:40pm Part of Safety Assessment of Extractables and Leachables under the New ICH Q3E Guideline (S11) Introduction to the ICH Q3E Draft Guideline: Extractables & Leachables - A Pharmaceutical Industry Perspective (S11-2) Chemical risk assessment · Regulatory Session Wed Nov 18 2:00pm–3:15pm The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Careers · with BioMarin 2:00pmConventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1)Boehringer Ingelheim 2:20pmTransitioning from Government Regulator to the Private Sector (S16-2)BlueRock Therapeutics 2:40pmSo You Want to Be a Consultant? (S16-3)Biologics Consulting
Boehringer Ingelheim Ingelheim, Germany
boehringer-ingelheim.com Pharmaceutical companies Family-owned German pharmaceutical company developing human medicines and animal health products.	Session Sun Nov 15 8:00am–11:30am First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Translational safety · with Novartis 8:00amFoundational Approaches to FIH Dose Selection (CE1-1)White Oak Regulatory Tox 8:20amModel-Informed Approaches to FIH Dose Prediction (CE1-2)Bedard ADME-Tox Solutions, Tango Therapeutics 8:45amCNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)Akkeri 9:10amInter-Species Dose Extrapolation for Ocular Therapeutics: Translational Frameworks for Eye-Delivered Products (CE1-4)Novartis 10:00amCrossing the Species Divide in Inhaled Dosing (CE1-5)Novartis 10:25amInteractive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6)Boehringer Ingelheim Session Sun Nov 15 8:00am–11:30am From Predictive Models to Collaborative Intelligence: The Role of Agentic AI in the Future of Toxicology (CE2) In silico and AI · with Human Chemical 8:00amWelcome and Course Overview (CE2-1)Human Chemical 8:05amAgentic AI 101: A Primer for Drug Discovery and Development Toxicologists (CE2-2)Taiho Oncology 8:30amAgentic AI Frameworks for Predictive Toxicology-Based Literature Searches (CE2-3)Coincidence Labs 9:00amSynthesizing Experimental Results and In-Silico Predictions for Autonomous Hypothesis Generation (CE2-4)Human Chemical 10:00amLeveraging Agentic AI to Reassess and Optimize Previously Failed Compounds (CE2-5)Ignota Labs 10:30amChemistry Foundation Models for Optimal Drug Design (CE2-6)deepmirror Talk Sun Nov 15 10:25am–11:30am Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1) Interactive Session: Hypothetical Challenge Scenarios in FIH Setting (CE1-6) Translational safety Poster Mon Nov 16 5:00pm–6:30pm IL-10–Associated Thrombocytopenia Is Not Mediated by Direct Platelet Effects (P129) Nelson Exhibit Ballroom · Poster P129 Immunotoxicology · Pathology Poster Mon Nov 16 5:00pm–6:30pm Strengthening Regulatory Confidence in Liver MPS: Insights from The 3Rs Collaborative’s & FDA CDER’s Cross Platform DILI Project (P213) Nelson Exhibit Ballroom · Poster P213 New approach methods · Regulatory Session Tue Nov 17 9:00am–12:00pm Next-Generation Liver Toxicity Assessment: Integrating Human-Relevant NAMs, AI, and Exposure Modeling (S07) New approach methods · In silico and AI · with Physicians Committee for Responsible Medicine 9:00amIntroduction (S07-1)Physicians Committee for Responsible Medicine 9:05amAn Integrated NAM Platform Combining Bioactivity Prediction with PBPK and Literature Intelligence for Chemical Liver Toxicity Assessment (S07-2)Human Chemical 9:30amMulticellular Hepatic In Vitro Models Using NANOSTACKS™: Flow-Driven Differential Toxicity and Human-Relevant Drug Response Prediction (S07-3)Revivocell 9:55amAI-Enabled, Exposure-Anchored DILI Prediction Using Human 3D Liver Microtissues (S07-4)InSphero 10:45amFrom Exposure Dynamics to Uncertainty: A Hybrid Framework for Drug-Induced Liver Injury Prediction (S07-5)ESQlabs 11:25amNovel Optical Techniques to Study Hepatic Microplastic Pollution: Optical Imaging as a Powerful New Approach Methodology (S07-6)University of New Mexico Talk Wed Nov 18 2:00pm–2:20pm Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16) Conventional and Unconventional Trajectories to a Toxicologist Career in the Pharmaceutical Sector (S16-1) Careers
Genentech South San Francisco, CA
gene.com Pharmaceutical companies Biotechnology company in the Roche Group that discovers, develops and markets medicines, chiefly in oncology, immunology and neuroscience.	Session Mon Nov 16 2:00pm–5:00pm In Vivo Gene Therapies: Breakthrough Innovations, Regulatory Roadmaps, and Development Challenges (S04) Biologics and new modalities · Regulatory · with Pfizer 2:00pmIntroduction (S04-1)Pfizer 2:10pmAdvanced Therapy Medicinal Products: The Journey from Innovation to Clinical Application (S04-2)Genentech 2:40pmMechanism-Driven Strategies for Translational Safety Success in Gene Therapy (S04-3)Attentive Science 3:45pmADME and Toxicology Considerations for the Advancement of Non-viral Gene Therapy Products (S04-4)Editas Medicine 4:15pmGene Therapy Nonclinical Development: Integrating Regulatory Expectations and Scientific Innovation (S04-5)Hartsough Nonclinical Consulting Talk Mon Nov 16 2:10pm–2:40pm Part of In Vivo Gene Therapies: Breakthrough Innovations, Regulatory Roadmaps, and Development Challenges (S04) Advanced Therapy Medicinal Products: The Journey from Innovation to Clinical Application (S04-2) Biologics and new modalities Poster Mon Nov 16 5:00pm–6:30pm A Comparative Analysis of In Vitro New Approach Methodologies for Human Neurotoxicity Screening (P503) Nelson Exhibit Ballroom · Poster P503 Neurotoxicology · New approach methods Session Tue Nov 17 2:00pm–5:00pm The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10) Safety pharmacology · with U.S. Food and Drug Administration 2:00pmTargeted Secondary Pharmacology Panels: Advantages and Applications (S10-1)U.S. Food and Drug Administration 2:15pmDeveloping And Validating Off-Target Screening Methods for New and Established Modalities (S10-2)Genentech 2:45pmAdvancing Secondary Pharmacology: Cross-Industry Insights and a Path Toward Global Harmonization (S10-3)UCB 3:45pmEvolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4)Johnson & Johnson 4:15pmA Regulatory Perspective on Secondary Pharmacology and Off-Target Assessments for Pharmaceutical Products (S10-5)U.S. Food and Drug Administration Talk Tue Nov 17 2:15pm–2:45pm Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10) Developing And Validating Off-Target Screening Methods for New and Established Modalities (S10-2) Safety pharmacology Talk Wed Nov 18 10:45am–11:10am Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13) The Complexity of Drug Development Illustrated with Nav1.7-Associated Dysautonomia (S13-4) Neurotoxicology
Sanofi Paris, France	◇Bronze Supporter
sanofi.com Pharmaceutical companiesBronze Supporter French global biopharmaceutical company developing and marketing medicines and vaccines, with a strong emphasis on immunology.	Session Sun Nov 15 8:00am–11:30am The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) DART · with Otsuka 8:00amThe ABCs of EFDs Introduction (CE3-1)Otsuka 8:05amDesigning a EFD Study (CE3-2)Amgen 8:30amSetting the EFD Testing Study Strategy (CE3-3)Sanofi 9:00amConducting an EFD Study: The Essentials of Getting it Right (CE3-4)Johnson & Johnson 10:00amInterpreting EFD Study Data (CE3-5)Lilly 10:35amCommunicating EFD Study Results (CE3-6) Talk Sun Nov 15 8:30am–9:00am Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3) Setting the EFD Testing Study Strategy (CE3-3) DART Talk Sun Nov 15 2:00pm–2:30pm Part of Beyond Animal Models: Navigating New Approach Methodologies in Modern Drug Development with Case Study Examples (CE5) Complex Human-Derived Models as New Approach Methodologies (NAMs) for Drug Discovery and Development (CE5-4) New approach methods Session Mon Nov 16 2:00pm–5:00pm Safety and Regulatory Roadmap for Immune Engagers: Strategies to Translate Novel Modalities (S05) Biologics and new modalities · Regulatory · with AstraZeneca 2:00pmIntroduction (S05-1)AstraZeneca 2:05pmMechanistic Toxicity of Immune Engagers: From Bench to Clinic (S05-2)AstraZeneca 2:30pmTranslating NAMs to First-in-Human Dose Selection and Regulatory Acceptance (S05-3)Certara 2:55pmSafety Assessment of Immune Engagers for Autoimmune Disease: An FDA Perspective (S05-4)U.S. Food and Drug Administration 3:45pmChallenging Case Studies: Clinical Translation and Risk Management in Immune Engager Trials (S05-5)University of Liverpool

Instantly find 20 buyers from pharmaceutical companies

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction

Instantly find 20 buyers from pharmaceutical companies

Browse ACT 2026 by